Abstracts tagged "autoimmune diseases"

Abstract Number: 0330 • ACR Convergence 2023
Patient-Reported Experiences and Comorbidities in Patients with IgG4-Related Disease with and Without Pancreatic Involvement
Liam Harvey¹, Guy Katz², Yasmin Hernandez-Barco², Ana Fernandes², Aubree McMahon², Grace McMahon², Isha Jha², Zachary Wallace³, Cory Perugino² and John Stone⁴, ¹Frank H. Netter School of Medicine at Quinnipiac University, New Haven, CT, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Newton, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: IgG4-Related Disease (IgG4-RD) is a systemic immune-mediated disease that commonly involves the pancreas in the form of autoimmune pancreatitis (AIP). Despite being one of…
Abstract Number: 0555 • ACR Convergence 2023
Evaluation and Management of the “False Positive” ANA and Undifferentiated Connective Tissue Disease Amongst Rheumatologists
Neha Gupta¹, Sarah Ford², Lane Scheiber², Tangada Rao² and Abhishek Nandan², ¹Virginia Commonwealth University Health Systems, Richmond, VA, ²Virginia Commonwealth University Health Systems; Veterans Affairs Medical Center, Richmond, VA
Background/Purpose: The management of a positive anti-nuclear antibody (ANA) is one of the most common consultations in rheumatology outpatient practice. The prevalence of a positive…
Abstract Number: 0798 • ACR Convergence 2023
A Novel 3D Model of Rheumatoid Arthritis Synovial Tissue Incorporating Fibroblasts, Endothelial Cells and Macrophages
Eva Philippon¹, Lisanne van Rooijen¹, Jan Piet van Hamburg¹, Fatemeh Khodadust¹, Conny Van der Laken² and Sander Tas³, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Amsterdam UMC - location VUMC, Amsterdam, Netherlands, ³Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: Rheumatoid Arthritis (RA) is a progressive and systemic autoimmune disorder associated with chronic and destructive inflammation of the joints. The hallmarks of RA are…
Abstract Number: 0996 • ACR Convergence 2023
Will Patients Engage with Digital Technologies as Part of Routine Healthcare?
Jeffrey R Curtis¹, Sandeep Sodhi², Yuji Su³, Scott Laster⁴, Fenglong Xie², Ye Liu⁵ and Corey Patrick⁴, ¹Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ²Illumination Health, Hoover, AL, ³University of Alabama at Birmingham and Illumination Health, Birmingham, AL, ⁴Micare, Memphis, TN, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM) are new care delivery options by which patients can provide data to their provider via…
Abstract Number: 1128 • ACR Convergence 2023
Refractory Inflammatory Ocular Pathology and Treatment with Janus Kinase Inhibitors. Multicenter Study and Literature Review
Carmen Lasa-Teja¹, Lara Sanchez-Bilbao², Jose Luis Martin-Varillas³, Vanesa Calvo Río⁴, José Luis Álvarez-Vega⁵, Emma Beltran-Catalan⁶, María del Mar Esteban-Ortega⁷, Santiago Muñoz⁷, Olga Maiz⁸, Ignacio Torre-Salaberri⁹, Ana Urruticoechea¹⁰, Elia Valls-Pascual¹¹, Raúl Veroz¹², Carmen Alvarez Reguera¹³, Rosalía Demetrio¹³ and Ricardo Blanco¹⁴, ¹Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology Group, Santander, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital de Laredo, Laredo, Spain, ⁴Valdecilla Hospital, Santander, Spain, ⁵Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁶HOSPITAL DEL MAR, Barcelona, Spain, ⁷Hospital Infanta Sofia, Madrid, Spain, ⁸Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ⁹Hospital Universitario de Basurto, Bilbao, Spain, ¹⁰Hospital Can Misses, Ibiza, Spain, ¹¹Hospital Universitario Doctor Peset. Alicante, Spain., Valencia, Spain, ¹²Hospital de Mérida, Mérida. Spain., Mérida, Spain, ¹³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Inflammatory ocular pathology (IOP) includes internal (uveitis) and external [mainly ocular surface pathology such as epi/scleritis and peripheral ulcerative keratitis (PUK)] involvement. IOP may…
Abstract Number: 1372 • ACR Convergence 2023
Obinutuzumab Efficacy and Tolerance in Patients with Auto-Immune Diseases Immunized Against Rituximab
Mathilde Pezot¹, Gaetane Nocturne², Rakiba Belkhir¹, Julien Henry¹, Stephan Pavy¹, Raphaele Seror³, Xavier Mariette⁴ and Samuel Bitoun⁵, ¹Rheumatology Department, Université Paris-Saclay, INSERM U1184, Hôpital Bicêtre, APHP, FHU CARE, Le Kremlin-Bicêtre, France, ²APHP, Le Kremlin-Bicêtre, France, ³University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁴Université Paris-Saclay, Le Kremlin-Bicêtre, France, ⁵CHU Bicêtre APHP, Le Kremlin-Bicêtre, France
Background/Purpose: Among patients with auto-immune diseases (AID) treated with Rituximab (RTX), anti-drug antibodies (ADAb) leading to inefficacy and infusion reactions (Wincup and al., Ann Rheum…
Abstract Number: 1590 • ACR Convergence 2023
Autoimmune Pathway Blockade by a Potent Orally Bioavailable STING Antagonist
Min Yang¹, Hailong Li¹, yangyang liu¹, lili yao¹, Jing Lin¹, Zhi xie² and Wenge zhong¹, ¹Regor Therapeutics, Shanghai, China, ²Regor Pharmaceuticals, Inc., San Francisco, CA
Background/Purpose: The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway has emerged as a key innate immune mediator of autoimmune and inflammatory diseases. However,…
Abstract Number: 1763 • ACR Convergence 2023
Asthma Severity Is Associated Increased Serum Anti-cyclic Antibody Level at Baseline and in Increase During Longitudinal Follow-up
Drayton Rorah¹, Linh Ngo², Mario Castro², Kristen Demoruelle³ and Scott Matson⁴, ¹University of Kansas Medical Center, Kansas City, KS, ²University of Kansas School of Medicine, Kansas City, KS, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Kansas School of Medicine, Kansas City, MO
Background/Purpose: The lung airways have been implicated in the pathogenesis of RA. RA-associated autoantibodies, including anti-cyclic citrullinated peptide (anti-CCP) antibodies are found to be generated…
Abstract Number: 1930 • ACR Convergence 2023
Blue Digit Syndrome as the Initial Presentation of Various Diseases: A Case Series
Raquel Ugena García¹, Juan José Lluch Galcerá², Cristina Calomarde Gomez¹, Ivette Casafont-Sole³ and Lourdes Mateo Soria², ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Badalona, Spain, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Blue Digit Syndrome (BDS) represents the cutaneous manifestation of numerous diseases that cause blue discoloration in one or more fingers in the absence of…
Abstract Number: 2105 • ACR Convergence 2023
Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases
Hiroaki Tanaka¹, Yukinori Okada², Shingo Nakayamada¹, Yusuke Miyazaki³, Kyuto Sonehara⁴, Shinichi Namba⁵, Suguru Honda⁶, Yuya Shirai⁷, Kenichi Yamamoto⁵, Katsunori Ikari⁸, Masayoshi Harigai⁹, KOSHIRO SONOMOTO¹⁰ and Yoshiya Tanaka¹, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²University of Tokyo / Osaka University / RIKEN, Tokyo, Japan, ³The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kiakyusyu Fukuoka, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Osaka University, Osaka, Japan, ⁶Tokyo Women's Medical University, Tokyo, Japan, ⁷Osaka University, Suita, Japan, ⁸Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁹Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ¹⁰University of Occupational and Environmental Health, Beppu, Japan
Background/Purpose: Autoimmune rheumatic diseases (AIRDs) are systemic but heterogeneous diseases characterized by orchestration of disrupted self-tolerance of immune systems. We face a challenge in characterizing…
Abstract Number: 2439 • ACR Convergence 2023
Proteomic and Genomic Profiling of Plasma Exosomes from Ankylosing Spondylitis Patients
Fataneh Tavasolian¹, starlee lively², Chiara Pastrello³, Michael Tang², Melissa Lim², Addison Pacheco², Zoya Qaiyum², Enoch Yau², Zeynep Baskurt⁴, Igor Jurisica⁵, Mohit Kapoor⁶ and Robert Inman², ¹Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ⁴Department of Biostatistics, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁶Division of Orthopaedics, Osteoarthritis Research Program, Schroeder Arthritis Institute, and Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Recent advances in understanding the biology of Ankylosing Spondylitis (AS) using innovative genomic and proteomic approaches offer the opportunity to address current challenges in…
Abstract Number: 2573 • ACR Convergence 2023
Prevalence of Pulmonary Hypertension in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features and Its Effect on Lung Disease Progression and Mortality
Michelle Ghebranious, Elena Joerns, Traci Adams and Trushil Shah, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a subset of interstitial lung disease (ILD) that manifests with interstitial pneumonia and features of autoimmunity while…
Abstract Number: 0016 • ACR Convergence 2023
Role of TP53 in Inflammatory Reprogramming of Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: TP53, a tumor-suppressor protein known as the guardian of the genome, plays a critical role in regulating genomic stability and cellular function. When TP53…
Abstract Number: 0086 • ACR Convergence 2023
Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Stephen Parmley, Benjamin Szylyk, Richard Frank, Matthew Hsu, Polina Brodsky, Cailin Sibley, Paul Lizzul and Martin Dahl, AnaptysBio, San Diego, CA
Background/Purpose: Checkpoint antagonist therapeutics have transformed the field of oncology while advancing the understanding of adequate checkpoint activity in preventing autoimmunity. Checkpoint agonism represents a…
Abstract Number: 0218 • ACR Convergence 2023
Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases
Yumeko Kawano¹, Xiaosong Wang¹, Naomi Patel², Grace Qian¹, Emily Kowalski¹, Katarina Bade³, Kathleen Vanni¹, Accelerating Medicines Partnership (AMP): RA/SLE¹, Zachary Williams², Claire Cook², Shruthi Srivatsan², Zachary Wallace⁴ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: During the height of the COVID-19 pandemic in the United States, tixagevimab/cilgavimab (Evusheld), a combination of monoclonal antibodies directed against the SARS-CoV2 spike protein,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].